

CME INSTITUTE

collective mindfulness

#Tweertorial: Parkinson's Disease Psychosis: Best Practices for Diagnosing PDP

April 11, 2023

[VIEW ON TWITTER](#)

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Faculty Affiliations

Michael Okun, MD

Department of Neurology
University of Florida College of Medicine
Gainesville, Florida

Emily Henderson, MBChB, MRCP, PhD

University of Bristol
Bristol, UK


Pamela Zeilman, APRN

Department of Neurology
University of Florida College of Medicine
Gainesville, Florida

Financial Disclosure

The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an "ineligible company" as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:



CME INSTITUTE

collective mindfulness

Dr. Okun has no financial disclosures.

Dr Henderson has received consulting fees from Abbvie and Bial; has received grant/research support from The Gatsby Foundation, National Institute of Health Research Health Technology Assessment, Elizabeth Blackwell Institute Health Data Strand, Engineering and Physical Sciences Research Council (EPSRC) Impact Acceleration Account, NIHR Research for Patient Benefit (RfPB) Programme, Alzheimer's UK Pump Priming Award, and British Geriatrics Society; has received honoraria for speaking/teaching from Kyowa Kirin, Abbvie, and Bial; has served on the advisory board for Abbvie; and received travel support from Bial.

Pamela Zeilman, MSN, has no financial disclosures.

Michael R. Page, PharmD, RPh

Independent Medical Director/Medical Writer

Plainsboro, New Jersey

Dr. Page is a consultant for BioCentric, Inc. and American Medical Communications, Inc.

None of the other planners, reviewers, and CME Institute staff for this educational activity have relevant financial relationships with ineligible companies to disclose. All relevant financial relationships have been mitigated.

Tweetorial References

Tweet #6

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019 [published correction appears in Lancet. 2020 Nov 14;396(10262):1562]. *Lancet*. 2020;396(10258):1204-1222.

[https://doi:10.1016/S0140-6736\(20\)30925-9](https://doi:10.1016/S0140-6736(20)30925-9)

Okunoye O, Marston L, Walters K, Schrag A. Change in the incidence of Parkinson's disease in a large UK primary care database. *NPJ Parkinsons Dis*. 2022;8(1):23. Published 2022 Mar 15. <https://doi:10.1038/s41531-022-00284-0>

Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. *J Neural Transm (Vienna)*. 2017;124(8):901-905. <https://doi:10.1007/s00702-017-1686-y>

Tweet #7

Greenland JC, Barker RA. The Differential Diagnosis of Parkinson's Disease. In: Stoker TB, Greenland JC, eds. *Parkinson's Disease: Pathogenesis and Clinical Aspects*. Brisbane (AU): Codon Publications; December 21, 2018

Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord*. 2015;30(12):1591-1601. <https://doi:10.1002/mds.26424>

Ward KM, Citrome L. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. *Neurol Ther*. 2018 Dec;7(2):233-248. <https://doi.org/10.1007/s40120-018-0105-0>



CME INSTITUTE

collective mindfulness

Tweet #8

Marsili L, Rizzo G, Colosimo C. Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease. *Front Neurol*. 2018;9:156. Published 2018 Mar 23. <https://doi:10.3389/fneur.2018.00156>

Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord*. 2015;30(12):1591-1601. <https://doi:10.1002/mds.26424>

Tweet #9

Marsili L, Rizzo G, Colosimo C. Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease. *Front Neurol*. 2018;9:156. Published 2018 Mar 23. <https://doi:10.3389/fneur.2018.00156>

Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord*. 2015;30(12):1591-1601. <https://doi:10.1002/mds.26424>

Tweet #10

Marsili L, Rizzo G, Colosimo C. Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease. *Front Neurol*. 2018;9:156. Published 2018 Mar 23. <https://doi:10.3389/fneur.2018.00156>

Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord*. 2015;30(12):1591-1601. <https://doi:10.1002/mds.26424>

Tweet #11

Marsili L, Rizzo G, Colosimo C. Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease. *Front Neurol*. 2018;9:156. Published 2018 Mar 23. <https://doi:10.3389/fneur.2018.00156>

Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord*. 2015;30(12):1591-1601. <https://doi:10.1002/mds.26424>

Tweet #12

Marsili L, Rizzo G, Colosimo C. Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease. *Front Neurol*. 2018;9:156. Published 2018 Mar 23. <https://doi:10.3389/fneur.2018.00156>

Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord*. 2015;30(12):1591-1601. <https://doi:10.1002/mds.26424>

Tweet #13

Mazzoni P, Shabbott B, Cortés JC. Motor control abnormalities in Parkinson's disease. *Cold Spring Harb Perspect Med*. 2012;2(6):a009282. <https://doi:10.1101/cshperspect.a009282>

Moustafa AA, Chakravarthy S, Phillips JR, et al. Motor symptoms in Parkinson's disease: A unified framework. *Neurosci Biobehav Rev*. 2016;68:727-740. <https://doi:10.1016/j.neubiorev.2016.07.010>



CME INSTITUTE

collective mindfulness

Tweet #14

Parkinson's Foundation. What is Parkinson's? <https://www.parkinson.org/understanding-parkinsons/what-is-parkinsons>. Accessed January 13, 2023.

Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. *Ann Neurol*. 2006;59(4):591-596. <https://doi:10.1002/ana.20834>

Tweet #15-20

Chaudhuri et al. NMSS. <https://www.movementdisorders.org/MDS-Files1/PDFs/Rating-Scales/NMSS.pdf>. Published 2007. Accessed January 13, 2023.

Tweet #21

Stang CD, Mullan AF, Camerucci E, et al. Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson's Disease (1991-2010). *J Parkinsons Dis*. 2022;12(4):1319-1327. <https://doi:10.3233/JPD-213035>

Tweet #22

Stang CD, Mullan AF, Camerucci E, et al. Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson's Disease (1991-2010). *J Parkinsons Dis*. 2022;12(4):1319-1327. <https://doi:10.3233/JPD-213035>

Tweet #23

Parkinson's Foundation. Hallucinations/Delusions. <https://www.parkinson.org/understanding-parkinsons/non-movement-symptoms/hallucinations-delusions>. Accessed January 13, 2023.

Stang CD, Mullan AF, Camerucci E, et al. Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson's Disease (1991-2010). *J Parkinsons Dis*. 2022;12(4):1319-1327. <https://doi:10.3233/JPD-213035>

Taddei RN, Cankaya S, Dhaliwal S, Chaudhuri KR. Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition. *Parkinsons Dis*. 2017;2017:3256542. <https://doi:10.1155/2017/3256542>

Chendo I, Fabbri M, Godinho C, et al. High frequency of psychosis in late-stage Parkinson's disease, *Clinical Parkinsonism & Related Disorders*. 2021;5(100119):2590-1125. <https://doi.org/10.1016/j.prdoa.2021.100119>

Tweet #24

Parkinson's Foundation. Hallucinations/Delusions. <https://www.parkinson.org/understanding-parkinsons/non-movement-symptoms/hallucinations-delusions>. Accessed January 13, 2023.

Stang CD, Mullan AF, Camerucci E, et al. Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson's Disease (1991-2010). *J Parkinsons Dis*. 2022;12(4):1319-1327. <https://doi:10.3233/JPD-213035>

Taddei RN, Cankaya S, Dhaliwal S, Chaudhuri KR. Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition. *Parkinsons Dis*. 2017;2017:3256542. <https://doi:10.1155/2017/3256542>

Chendo I, Fabbri M, Godinho C, et al. High frequency of psychosis in late-stage Parkinson's disease, *Clinical Parkinsonism & Related Disorders*. 2021;5(100119):2590-1125. <https://doi.org/10.1016/j.prdoa.2021.100119>



CME INSTITUTE
collective mindfulness

GLOSSARY

MDS Movement Disorder Society

PD Parkinson's Disease

PDP Parkinson's Disease Psychosis